Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)

Phase 2

Terminated

Conditions: Mesothelioma, Malignant

Interventions: Drug: Placebo
Drug: Amatuximab
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2015-02-06

Last Posted Date: 2020-03-17

Lead Sponsor: Morphotek

Target Recruit Count: 124

Registration Number: NCT02357147

A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

Phase 3

Completed

Conditions: Metastatic Head and Neck Cancer
Recurrent Head and Neck Cancer

Interventions: Biological: Pembrolizumab
Drug: Carboplatin
Drug: Cisplatin
Drug: 5-FU
Biological: Cetuximab

First Posted Date: 2015-02-06

Last Posted Date: 2024-06-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 882

Registration Number: NCT02358031

ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers

Phase 1

Completed

Conditions: Biliary Tract Cancer
Gallbladder Cancer
Cholangiocarcinoma
Ampullary Cancer

Interventions: Drug: Acelarin
Drug: Cisplatin

First Posted Date: 2015-01-30

Last Posted Date: 2023-05-17

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 21

Registration Number: NCT02351765

Locations: 🇬🇧
Beatson Oncology Centre, Glasgow, United Kingdom
🇬🇧
Clatterbridge Cancer Centre, Liverpool, United Kingdom
🇬🇧
Imperial College London, London, United Kingdom

and more 2 locations

Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

Phase 1

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Patritumab
Drug: Cetuximab
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2015-01-30

Last Posted Date: 2018-09-11

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 15

Registration Number: NCT02350712

Locations: 🇬🇧
University College London Hospital, London, United Kingdom
🇬🇧
The Royal Marsden Hospital, London, United Kingdom

Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer

Phase 4

Conditions: Small Cell Lung Cancer

Interventions: Drug: Etoposide
Drug: Irinotecan
Drug: Cisplatin

First Posted Date: 2015-01-28

Last Posted Date: 2016-12-05

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 308

Registration Number: NCT02348450

Locations: 🇨🇳
WuHan Tongji Hospital, WuHan, Hubei, China
🇨🇳
LiaoNing Provincial Tumor Hospital, Shenyang, Liaoning, China
🇨🇳
The second affiliated hospital of zhejiang university school of medicine, Hangzhou, Zhejiang, China

and more 17 locations

A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma

Phase 1

Completed

Conditions: Malignant Pleural Mesothelioma
Non-Small Cell Lung Cancer

Interventions: Drug: BBI608
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2015-01-28

Last Posted Date: 2022-04-12

Lead Sponsor: Sumitomo Pharma Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT02347917

Locations: 🇯🇵
National Cancer Center Hospital, Tokyo, Japan
🇯🇵
National Cancer Center Hospital East, Chiba, Japan

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Primary Mediastinal B-cell Lymphoma (PMBCL)
Transformed Follicular Lymphoma (TFL)
High Grade B-cell Lymphoma (HGBCL)
Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Relapsed Diffuse Large B-Cell Lymphoma

Interventions: Biological: Axicabtagene Ciloleucel
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Levetiracetam
Drug: Tocilizumab
Drug: Dexamethasone
Drug: Doxorubicin
Drug: High-dose methylprednisolone
Drug: Prednisone
Drug: Bendamustine
Drug: Vincristine
Drug: Rituximab
Drug: Ifosfamide
Drug: Carboplatin
Drug: Methylprednisolone
Drug: Etoposide
Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Cisplatin

First Posted Date: 2015-01-28

Last Posted Date: 2024-06-04

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 307

Registration Number: NCT02348216

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
University of California Los Angeles (UCLA), Santa Monica, California, United States
🇨🇦
Princess Margaret, Toronto, Ontario, Canada

and more 33 locations

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Selumetinib
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2015-01-13

Last Posted Date: 2024-03-21

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 62

Registration Number: NCT02337530

Locations: 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada
🇨🇦
CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada

and more 9 locations

A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)

Phase 2

Completed

Conditions: Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Biological: pembrolizumab
Drug: cisplatin
Drug: 5-FU
Drug: capecitabine

First Posted Date: 2015-01-09

Last Posted Date: 2022-08-08

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 318

Registration Number: NCT02335411

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB

Phase 2

Terminated

Conditions: Activating EGFR Mutation
Non-squamous Non-small Cell Lung Cancer Stage IIIA
Non-squamous Non-small Cell Lung Cancer Stage IIIB
NSCLC
Non-squamous Non-small Cell Lung Cancer Stage II

Interventions: Drug: Gefitinib
Drug: docetaxel
Drug: cisplatin
Procedure: Surgery

First Posted Date: 2014-12-29

Last Posted Date: 2018-01-23

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 1

Registration Number: NCT02326285

Locations: 🇩🇪
Pius-Hospital, Oldenburg, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy